Clinical

Dataset Information

0

Effect of pre-operative exercise on cardiovascular fitness in patients undergoing surgery for major upper gastro-intestinal cancer.


ABSTRACT: Interventions: Participants will attend a hospital gym for a structured and supervised high intensity interval exercise program over three sessions per week for 4 weeks pre-operatively. Each participant will have a prescibed exercise program by a physiotherapist. Each supervised session will comprise of at least 30 minutes of aerobic exercise in the form of a walking program, and a cycling program on an electromagnetically braked cycle ergometer. The walking program will be prescribed at a walking speed equal to 80% of the average speed achieved during the 6MWT. The cycling program will be prescribed at = 60% of peak power achieved during the CPET. Progression of the intensity and duration of the program’s aerobic components, both supervised and unsupervised, will be titrated to a dyspnoea score of 4-6 (Borg scale) or a rating of perceived exertion (RPE) of 14-16 depending on the symptom of exercise limitation Primary outcome(s): Change in mean anaerobic threshold as determined by; - Proportion of participants achieving an increase of at least 1.8mL/kg/min as determined by serial cardiopulmonary exercise testing prior and following participation in exercise program. CPET testing will be performed on a calibrated electronically-braked cycle ergometer. The rate at which power will increase each minute will be individualised, with the aim of achieving a test duration of between 8 and 12 minutes. Breath-by-breath expired gas analysis will be undertaken using a Medisoft Exp’air metabolic cart. Peak exercise capacity will be defined as the rate of oxygen consumption averaged over the final 20 second epoch of the CPET. Lactate threshold will be determined using the ‘combined method[time point of initial CPET is following the first clinic visit to book surgery and the final CPET is in the week prior to surgery] Study Design: Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy

DISEASE(S): Surgery-other Surgery,Anaesthesiology-anaesthetics,Cancer-oesophageal (gullet),Cancer Involving The Upper Gastrointestinal Tract, Including Oesophagus, Stomach, Duodenum, Pancreas, Liver And Bile Duct

PROVIDER: 2465036 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2013-11-16 | E-GEOD-27536 | biostudies-arrayexpress
| 2430473 | ecrin-mdr-crc
| 57986 | ecrin-mdr-crc
2014-09-01 | E-GEOD-27543 | biostudies-arrayexpress
2024-01-16 | GSE214282 | GEO
2022-12-31 | E-MTAB-11166 | biostudies-arrayexpress
2024-01-16 | GSE236402 | GEO
| 2150258 | ecrin-mdr-crc
| 2472407 | ecrin-mdr-crc
| 2603510 | ecrin-mdr-crc